12 May 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Ixazomib citrate (Ninlaro)
  
• Blinatumomab (Blincyto)
  
• Emtricitabine with tenofovir alafenamide fumarate (Descovy)
  
• Oseltamavir phosphate (Tamiflu)
  
• Cholic acid (Kolbam)
  
• Benzalkonium chloride (Femadexil)
  

Read TC agenda [French]